• Home
  • E-submission
  • Sitemap
  • Contact us
  • Search
  • Advanced Search
Intest Res Search

CLOSE

‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

December 1, 2020


Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res. 2021;19(4):360-364.

Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival....

Review

November 25, 2020


Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res. 2021;19(4):365-378.

Over recent years, inflammatory bowel diseases have become an issue of increased attention in daily clinical practice, due to both a rising incidence and improved imaging capability in detection. In...

Review

November 6, 2020


An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

In late 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated in Wuhan, Hubei province, China. The major clinical symptoms described for coronavirus disease...

Original Article

December 1, 2020


Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data...

Original Article

November 20, 2020


Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Background/Aims: Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and...

Original Article

November 20, 2020


Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Background/Aims: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up...

Original Article

November 10, 2020


Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan....

Original Article

November 9, 2020


Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.
Intest Res. 2021;19(4):430-437.

Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal...

Original Article

November 6, 2020


High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.
Intest Res. 2021;19(4):438-447.

Background/Aims: Predictors of short-term outcome of intravenous (IV) steroid therapy in acute severe ulcerative colitis (ASUC) have been well described, but the impact of cytomegalovirus (CMV) infection as a predictor...

Original Article

August 18, 2020


Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Intest Res. 2021;19(4):448-460.

Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy...

Original Article

August 18, 2020


Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.
Intest Res. 2021;19(4):461-467.

Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)...
Current Issue
Volume 19(4); Oct 2021
Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intest Res. 2021;19(4):357-359.

Editorial

Epub October 26, 2021
Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res. 2021;19(4):360-364.

Review

Epub December 1, 2020
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res. 2021;19(4):365-378.

Review

Epub November 25, 2020
An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

Review

Epub November 6, 2020
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Original Article

Epub December 1, 2020
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Original Article

Epub November 20, 2020
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Original Article

Epub November 20, 2020
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Original Article

Epub November 10, 2020
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.
Intest Res. 2021;19(4):430-437.

Original Article

Epub November 9, 2020
High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.
Intest Res. 2021;19(4):438-447.

Original Article

Epub November 6, 2020
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Intest Res. 2021;19(4):448-460.

Original Article

Epub August 18, 2020
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.
Intest Res. 2021;19(4):461-467.

Original Article

Epub August 18, 2020
Hydroxyurea associated ileocecal valve ulcer: evidence for causality
Thevaraajan Jayaraman, Ruveena Bhavani Rajaram, Gin Gin Gan, et al.
Intest Res. 2021;19(4):468-471.

Case Report

Epub December 1, 2020
Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
Eun Sil Kim, Ji Hyung Park, Yon Ho Choe, et al.
Intest Res. 2021;19(4):472-477.

Case Report

Epub October 29, 2020
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, et al.
Intest Res. 2021;19(4):478-481.

Brief Communcation

Epub October 26, 2021
An elderly woman with severe enteritis mimicking infectious enteritis
Kazunori Nagashima, Takashi Kato, Taichi Kimura, et al.
Intest Res. 2021;19(4):482-484.

Image of the issue

Epub July 3, 2020
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD
ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2021 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next